Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer

Dysregulation of mRNA alternative splicing is prevalent in cancers. Here, the authors characterized the landscape of aberrant alternative splicing during the development of prostate cancer, progression and therapeutic resistance and show that splicing modulator, E7107, reduces growth in castration-r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dingxiao Zhang, Qiang Hu, Xiaozhuo Liu, Yibing Ji, Hsueh-Ping Chao, Yan Liu, Amanda Tracz, Jason Kirk, Silvia Buonamici, Ping Zhu, Jianmin Wang, Song Liu, Dean G. Tang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/7650acc90f58486d8e0f1601efde26ba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7650acc90f58486d8e0f1601efde26ba
record_format	dspace
spelling	oai:doaj.org-article:7650acc90f58486d8e0f1601efde26ba2021-12-02T14:40:38ZIntron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer10.1038/s41467-020-15815-72041-1723https://doaj.org/article/7650acc90f58486d8e0f1601efde26ba2020-04-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-15815-7https://doaj.org/toc/2041-1723Dysregulation of mRNA alternative splicing is prevalent in cancers. Here, the authors characterized the landscape of aberrant alternative splicing during the development of prostate cancer, progression and therapeutic resistance and show that splicing modulator, E7107, reduces growth in castration-resistant prostate cancer.Dingxiao ZhangQiang HuXiaozhuo LiuYibing JiHsueh-Ping ChaoYan LiuAmanda TraczJason KirkSilvia BuonamiciPing ZhuJianmin WangSong LiuDean G. TangNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-19 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Dingxiao Zhang Qiang Hu Xiaozhuo Liu Yibing Ji Hsueh-Ping Chao Yan Liu Amanda Tracz Jason Kirk Silvia Buonamici Ping Zhu Jianmin Wang Song Liu Dean G. Tang Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer
description	Dysregulation of mRNA alternative splicing is prevalent in cancers. Here, the authors characterized the landscape of aberrant alternative splicing during the development of prostate cancer, progression and therapeutic resistance and show that splicing modulator, E7107, reduces growth in castration-resistant prostate cancer.
format	article
author	Dingxiao Zhang Qiang Hu Xiaozhuo Liu Yibing Ji Hsueh-Ping Chao Yan Liu Amanda Tracz Jason Kirk Silvia Buonamici Ping Zhu Jianmin Wang Song Liu Dean G. Tang
author_facet	Dingxiao Zhang Qiang Hu Xiaozhuo Liu Yibing Ji Hsueh-Ping Chao Yan Liu Amanda Tracz Jason Kirk Silvia Buonamici Ping Zhu Jianmin Wang Song Liu Dean G. Tang
author_sort	Dingxiao Zhang
title	Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer
title_short	Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer
title_full	Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer
title_fullStr	Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer
title_full_unstemmed	Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer
title_sort	intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/7650acc90f58486d8e0f1601efde26ba
work_keys_str_mv	AT dingxiaozhang intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT qianghu intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT xiaozhuoliu intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT yibingji intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT hsuehpingchao intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT yanliu intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT amandatracz intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT jasonkirk intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT silviabuonamici intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT pingzhu intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT jianminwang intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT songliu intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer AT deangtang intronretentionisahallmarkandspliceosomerepresentsatherapeuticvulnerabilityinaggressiveprostatecancer
_version_	1718390180183801856

Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer

Ejemplares similares